JP2004059439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004059439A5 JP2004059439A5 JP2002216039A JP2002216039A JP2004059439A5 JP 2004059439 A5 JP2004059439 A5 JP 2004059439A5 JP 2002216039 A JP2002216039 A JP 2002216039A JP 2002216039 A JP2002216039 A JP 2002216039A JP 2004059439 A5 JP2004059439 A5 JP 2004059439A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- octenyl
- oxocyclopentyl
- bone
- cyc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2-Heptanoyloxyethyl Chemical group 0.000 claims 14
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 231100000252 nontoxic Toxicity 0.000 claims 5
- 230000003000 nontoxic effect Effects 0.000 claims 5
- 150000003180 prostaglandins Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 5
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002216039A JP4419368B2 (ja) | 2002-07-25 | 2002-07-25 | プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002216039A JP4419368B2 (ja) | 2002-07-25 | 2002-07-25 | プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009230262A Division JP2010006835A (ja) | 2009-10-02 | 2009-10-02 | プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004059439A JP2004059439A (ja) | 2004-02-26 |
| JP2004059439A5 true JP2004059439A5 (enExample) | 2005-09-29 |
| JP4419368B2 JP4419368B2 (ja) | 2010-02-24 |
Family
ID=31937902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002216039A Expired - Fee Related JP4419368B2 (ja) | 2002-07-25 | 2002-07-25 | プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4419368B2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005235309B2 (en) | 2004-04-19 | 2012-07-26 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| AU2009348470B2 (en) | 2009-06-24 | 2015-04-02 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| WO2010151241A1 (en) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
| US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
| CN103429247A (zh) | 2010-12-29 | 2013-12-04 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
| US11207417B2 (en) | 2017-03-14 | 2021-12-28 | Polyactiva Pty Ltd | Drug-polymer conjugate |
| IL269321B (en) * | 2017-03-14 | 2022-07-01 | Polyactiva Pty Ltd | Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer |
| US11696955B2 (en) | 2017-03-14 | 2023-07-11 | Polyactiva Pty Ltd | Drug-polymer conjugate |
| CN121022737A (zh) * | 2025-10-30 | 2025-11-28 | 成都生基赛尔生物科技有限公司 | 一种脐带间充质干细胞成骨诱导分化培养基及培养方法 |
-
2002
- 2002-07-25 JP JP2002216039A patent/JP4419368B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1188422C (zh) | 钙(3s)四氢－3－呋喃基(1s,2r)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苯甲基－2－(膦酰氧基]丙基氨基甲酸酯 | |
| JP2004059439A5 (enExample) | ||
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| JP2004514663A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JPWO2001037877A1 (ja) | 骨量低下疾患治療剤 | |
| JP2002519305A5 (enExample) | ||
| CN101535240B (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的前列腺素及相关化合物的前药 | |
| US20060281715A1 (en) | Phosphates of secondary alcohols | |
| JP2002541242A (ja) | 医薬化合物 | |
| WO2012162175A1 (en) | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same | |
| CN100531739C (zh) | 碳2位修饰的19-去甲-维生素d类似物在制备诱导新骨生成药物中的应用 | |
| TW200403059A (en) | Combination of a reflux inhibitor and an imidazopyridine for the treatment of gerd | |
| JP4419368B2 (ja) | プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤 | |
| JPH0227970B2 (enExample) | ||
| JP3588369B2 (ja) | ラクトン化合物及びその製造方法 | |
| AU2005216651A1 (en) | Treatment of interstitial cystitis with vitamin D compounds | |
| WO2015155262A1 (fr) | Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline | |
| US20030166622A1 (en) | Vitamin D derivatives with acyloxy groups in the side chains, process for their production, and the use for the production of pharmaceutical agents | |
| JP2003520760A (ja) | 感染症の治療および予防処置用医薬製剤の製造のための、または植物における殺真菌剤、殺菌剤もしくは除草剤としての使用 | |
| JP6030168B2 (ja) | 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ | |
| CN100367948C (zh) | 三环－[5.2.1.02.6]－癸－9－基－黄原酸酯的纯立体异构体的制备和由其制成的药物 | |
| KR20020012293A (ko) | 치료제 | |
| RU2299886C2 (ru) | Соединения, их применение для лечения нарушений портальной и печеночной венозной циркуляции | |
| JP6306067B2 (ja) | 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ |